Sialix, Inc.

Sialix, Inc. is a biotechnology firm dedicated to developing monoclonal and polyclonal antibodies, as well as recombinant lab reagents, primarily for cancer research and immunology applications. Founded in 2006 and headquartered in Newton, US, Sialix, Inc. specializes in supplying vital reagents for life sciences research.

The company has pursued five deals with its latest funding being a Series B round in June 2014, raising USD 0. 53 mn, bringing the total amount raised to USD 0. 53 mn and its current valuation at USD 7. 442 mn.

Sialix Cancer Research specializes in the development and supply of monoclonal antibodies, polyclonal antibodies, and recombinant lab reagents designed for research applications in the life sciences sector. Their primary offerings cater to the needs of laboratories engaged in cancer research, immunology, and serological testing, particularly in the context of diseases like Chagas disease. The company’s products are utilized in various assays, including enzyme-linked immunosorbent assays (ELISAs), providing researchers with critical tools for diagnostic testing and therapeutic development. Sialix's clientele includes academic institutions, biotechnology firms, and healthcare organizations primarily located in North America, Europe, and select markets in Asia, ensuring that their innovative solutions reach a global audience committed to advancing medical and scientific knowledge.

Sialix Cancer Research generates revenue through direct sales of their specialty reagents and antibodies to research laboratories and medical institutions. The company employs a B2B transaction model where clients place orders based on specific research needs, often benefiting from tailored solutions that address their unique project requirements. Pricing structures are established for individual products, with potential for bulk purchasing agreements for larger institutions, facilitating a steady flow of recurring revenue. The company's flagship products, particularly its monoclonal antibodies and customized ELISA kits, play a crucial role in securing contracts with laboratories focused on cancer diagnostics and treatment.

Through strategic partnerships and collaborations with distributors, Sialix strengthens its market presence and enhances its revenue streams, ensuring that it remains a key player in the research reagent sector. Sialix, Inc. aims to expand its product line by launching new monoclonal antibodies tailored for emerging cancer research needs, with releases planned for late 2024. In addition, the company is targeting expansion into the Asian markets, specifically China and Japan, by 2025.

The most recent funding round of USD 0. 53 mn will be utilized to support these product developments and market entry strategies.